Safety
Tirzepatide Contraindications and Warnings
Approved tirzepatide labelling contraindicates use in people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, and in those with prior serious hypersensitivity to tirzepatide. A boxed warning describes thyroid C-cell tumours observed in rodents, with human relevance undetermined.
Key takeaways
- Personal or family history of medullary thyroid carcinoma is a labelled contraindication.
- Multiple endocrine neoplasia syndrome type 2 is a labelled contraindication.
- Prior serious hypersensitivity to tirzepatide contraindicates further use.
- A boxed warning describes rodent thyroid C-cell tumours; human relevance is undetermined.
- Family history matters — many people do not know a relative's thyroid cancer subtype.
| Contraindication 1 | Personal or family history of medullary thyroid carcinoma |
|---|---|
| Contraindication 2 | Multiple endocrine neoplasia syndrome type 2 (MEN2) |
| Contraindication 3 | Prior serious hypersensitivity to tirzepatide or excipients |
| Boxed warning | Thyroid C-cell tumours in rodents; human relevance undetermined |
| Other labelled warnings | Pancreatitis, gallbladder disease, severe GI reactions, hypoglycaemia with insulin or secretagogues, diabetic retinopathy complications, acute kidney injury |
| Pregnancy | Not recommended |
Why does family history matter so much here?
Because medullary thyroid carcinoma has a strong hereditary component through MEN2, and a family history changes the assessment even when the patient has no diagnosis themselves. The practical problem is that most people know a relative had 'thyroid cancer' without knowing the subtype — and medullary is a minority of thyroid cancers.
This is a concrete reason why a two-minute online intake form is inadequate. The right answer often requires someone to go and ask a family member.
What warnings sit below the contraindication level?
Labelling describes pancreatitis, gallbladder disease, severe gastrointestinal reactions, hypoglycaemia when combined with insulin or insulin secretagogues, diabetic retinopathy complications in people with type 2 diabetes, acute kidney injury associated with severe gastrointestinal effects, and hypersensitivity reactions.
These are not absolute barriers but factors a prescriber weighs, sometimes with additional monitoring.
Do compounded products carry the same warnings?
The molecule's risks do not disappear because the preparation is compounded. What differs is that a compounded product has not been through the review that produced that labelling, may not be supplied with equivalent information, and its adverse events are captured less systematically.
Assuming a compounded product is safer because its packaging says less would be exactly backwards.
What the evidence shows
- Labelled contraindications and warnings from approved prescribing information.
- A hereditary basis for the thyroid-related contraindication.
What the evidence does not show
- Whether tirzepatide is safe for you — that requires clinical assessment.
- That the rodent thyroid finding establishes human risk.
Related: Side effects · Eligibility
How much does each dose step actually add?
| Dose | Mean reduction |
|---|---|
| 2.5 mg | 0% |
| 5 mg | 15.0% |
| 10 mg | 19.5% |
| 15 mg | 20.9% |
| Group | Tirzepatide | Semaglutide |
|---|---|---|
| Discontinued for GI effects | 2.7% | 5.6% |
Why is family history treated as seriously as personal history?
Medullary thyroid carcinoma has a strong hereditary component, transmitted particularly through multiple endocrine neoplasia syndrome type 2. A person may carry the predisposing genetics without any personal diagnosis, which is why labelling treats a family history as contraindicating rather than merely cautionary.
This is the single detail most likely to be missed at intake, because people do not naturally think of a relative's thyroid cancer as part of their own medical history. It is worth volunteering rather than waiting to be asked, and an intake process that does not ask is telling you something about its quality.
What requires evaluation without being an absolute contraindication?
Several situations call for specific assessment rather than automatic exclusion: a history of pancreatitis, gallbladder disease, severe gastrointestinal conditions including gastroparesis, significant renal impairment, and concurrent use of insulin or a sulfonylurea. Pregnancy, planned pregnancy, and breastfeeding require their own discussion.
The distinction matters because it is frequently collapsed. An absolute contraindication means the drug should not be used. A situation requiring evaluation means a clinician weighs the specific circumstances. Neither determination can be made from a webpage, and a service that treats a checkbox form as sufficient for either has substituted convenience for assessment.
What does this page cover, and what does it deliberately leave out?
This page addresses Label contraindications and boxed warning and clinical assessment, organised around the primary question of tirzepatide contraindications. Each of those elements is treated separately below rather than blended, because they carry different evidence weights and a reader is entitled to know which parts rest on randomised data and which rest on a captured commercial claim or a regulatory document.
| Element | Treatment here | Evidence basis |
|---|---|---|
| Label contraindications | Covered on this page | Primary evidence |
| Boxed warning and clinical assessment | Covered on this page | Primary evidence |
| Individualized clinical instruction | Deliberately not covered | Belongs with your prescriber or dispensing pharmacist |
What are the limits of what this page can tell you?
Every page on this site rests on a specific labelled dosing framework, and that record has boundaries worth stating plainly rather than leaving a reader to discover them. The limitations below are specific to the material presented above.
- The evidence here describes groups, populations, or captured records — it does not describe you, and no page can substitute for your prescriber or dispensing pharmacist.
- Figures carry the date on which they were verified. In a market where terms change frequently, an undated figure functions as a claim about the present that nobody has checked.
- Elements marked Verification Pending are genuinely unknown to this publication rather than merely omitted for brevity, and should not be inferred from surrounding content.
- Where a source conflicts with another, this site shows the conflict rather than resolving it, which means some questions are left open on purpose.
What would change the conclusion on this page?
Any of the following would change what this page concludes:
- New primary evidence bearing directly on tirzepatide contraindications.
- A change to FDA labelling affecting any statement made above.
- A verified correction submitted through the corrections process and accepted on the evidence.
- A material change to a captured record, including a price, term, or regulatory status.
- Completion of a verification currently marked pending, which would replace a gap with a stated fact.
What do the technical terms on this page mean?
Definitions for the 9 technical terms this page uses, including MEN2, boxed warning, compounded, contraindication — in the specific sense used above.
| MEN2 | Multiple endocrine neoplasia syndrome type 2. An inherited condition that predisposes to medullary thyroid carcinoma, and a labelled contraindication to tirzepatide. |
|---|---|
| boxed warning | The most serious warning the FDA requires on a drug label. Tirzepatide carries one concerning thyroid C-cell tumours observed in rodent studies. |
| compounded | Prepared by a pharmacy rather than manufactured under an approved application. Compounded tirzepatide is not FDA approved and has not been evaluated in any randomised trial. |
| contraindication | A circumstance in which a drug should not be used at all. For tirzepatide these include a personal or family history of medullary thyroid carcinoma and MEN2. |
| excipient | An inactive ingredient in a formulation. Excipients affect stability, tolerability, and injection-site reactions, and can differ between compounded preparations and the approved product. |
| hypoglycaemia | Abnormally low blood glucose. Uncommon with tirzepatide alone because its insulin effect is glucose-dependent, but meaningfully more likely when combined with insulin or a sulfonylurea. |
| medullary thyroid carcinoma | A form of thyroid cancer with a strong hereditary component. A personal or family history of it is a labelled contraindication to tirzepatide. |
| pancreatitis | Inflammation of the pancreas. It appears in tirzepatide labelling as a serious potential adverse event, and presents characteristically as severe upper abdominal pain radiating to the back. |
| sulfonylurea | A class of oral diabetes medication that stimulates insulin release regardless of glucose level, which is why combining it with tirzepatide raises hypoglycaemia risk. |
Frequently asked questions
Who should not take tirzepatide?
People with personal or family history of medullary thyroid carcinoma, MEN2, or prior serious hypersensitivity to tirzepatide.
What is the boxed warning?
It describes thyroid C-cell tumours observed in rodent studies; human relevance is undetermined.
Why does family history of thyroid cancer matter?
Medullary thyroid carcinoma has a strong hereditary component through MEN2, so family history changes the assessment.
Do compounded versions carry the same risks?
The molecule's risks remain, but compounded products have not been through the same review and their adverse events are captured less systematically.
Change history
| Date | Change |
|---|---|
| 2026-07-22 | Page published with current dataset snapshot. |
Dates change only for substantive edits, never for cosmetic changes. Corrections: corrections policy.